

# AI Reputation Analysis and Signal Evaluation - Eylea (Regeneron Pharmaceuticals)

## BRAND AI REPUTATION

Medical Devices, Pharma & Biotech  
Reputation: Eylea (Regeneron Pharmaceuticals) (eylea.us)

<https://eylea.us>

Industry: Medical Devices, Pharma & Biotech



REPUTATION LEVEL

## MEDICAL DEVICES, PHARMA & BIOTECH

**59.3 Avg Reputation**

Based on 784 businesses audited.

### LOWER REPUTATION THAN AVERAGE

Eylea (Regeneron Pharmaceuticals) has 25.3 points less reputation than the average for Medical Devices, Pharma & Biotech.

## EXPERT VERDICT

The site is a clinical and informational dead zone that provides zero substance to back its pharmaceutical domain signal. It serves as a technical barricade rather than a professional resource, resulting in a high BS score due to the total opacity of its claims. Any authority implied by the domain name is immediately negated by the absence of verifiable proof and identity structures.

[See how to improve >](#)

## INFO DENSITY

Power-words vs. Substance ratio.

5

17% Reputation

The information density is near zero as the content consists entirely of technical bot-blocking error messages rather than business or clinical substance. There are no H1-H4 headings present, resulting in a 100% absence of strategic nouns or measurable outcomes. The body text contains 0 specific pharmaceutical claims, containing only technical strings such as IP address 77.37.37.89 and error code 0.240f1502. This total lack of substance across the 286-character count results in maximum penalties for specificity absence.

## SEMANTIC COHERENCE

Homepage promise vs. Sub-page reality.

0

0% Reputation

There is an absolute drift between the primary signal of a pharmaceutical product (Eylea) and the substance of a 'Site Maintenance' technical page. The homepage hero section, which is expected to deliver therapeutic value propositions, instead delivers a security warning, representing an 8-point alignment failure. Because sub-pages are inaccessible or non-existent in the crawl, the site fails to provide any consistent messaging or supporting evidence for the brand's existence. The heading hierarchy is non-existent, scoring 5 points for total structural incoherence.

## TRUST & PROOF

Verifiable evidence vs. Trust Theatre.

15

75% Reputation

### DIAGNOSIS: TRUST THEATRE

The review\_count and proof\_links\_count are both zero, indicating a complete lack of verified trust signals or external validation. No performance claims are made in the text, so no active 'trust theatre' is detected; however, the site fails to provide a single proof path to regulatory filings or clinical trial data. This absence of outbound validation for a medical product results in a maximum proof path penalty. The site essentially functions as a verification vacuum.

### EVIDENCE: PROOF DENSITY

The ratio of verifiable evidence to assertions is undefined, as the site contains neither. There are exactly zero proof points present across the page data, against an industry expectation of dense clinical and regulatory citations. The only verifiable data points are technical error metrics, which provide zero evidence regarding the efficacy or safety of the pharmaceutical product the domain represents.

## COMMODITY FINGERPRINT

Detection of industry cliches/templates.

9

60% Reputation

The content uses the most generic form of technical boilerplate language, specifically a bot-detection and site maintenance template. There are zero matches for industry-specific jargon such as 'FDA cleared' or 'clinical trial data' because the site is functionally empty. This 'Site Maintenance' placeholder is a universal commodity fingerprint that could be applied to any domain in any industry. The value proposition is entirely non-unique, providing 0% differentiation for the Eylea brand.

## IDENTITY & AUTHORITY

Expert verifiability & Schema depth.

5

33% Reputation

### DIAGNOSIS: AUTHORITY GAPS

The site lacks any schema\_json or structured data to establish organizational identity or medical authority. There is no digital footprint for experts, founders, or medical professionals within the crawled text, leading to a total authority gap. The technical implementation of a bot-block on a primary product domain represents a significant technical credibility gap for a multi-billion dollar biotech entity. No sameAs links or Person schema are present to verify the brand's legitimacy.

### EVIDENCE: PERFORMANCE VS. CLAIMS

The site makes no marketing performance claims because it provides no content, creating a total disconnect from the known market status of the medication. The marketing tone is entirely replaced by a technical security tone, which fails to demonstrate any of the 'breakthrough innovation' suggested by the industry patterns. There are no results, case studies, or patient outcomes provided to substantiate the therapeutic signal of the domain.

[See how to improve >](#)

## INDUSTRY MATCH & SCORE SUMMARY

**Medical Devices, Pharma & Biotech Reputation: Eylea (Regeneron Pharmaceuticals) (eylea.us)**

**Reputation: 34 / 100**

### INDUSTRY CLASSIFICATION

The domain suggests a prominent pharmaceutical product for retinal diseases, yet the content is entirely restricted to a security bot-blocking message and maintenance meta-tag. This creates a total mismatch between the high-stakes clinical industry classification and the actual technical delivery of the site.

*"The score of 34 is primarily driven by the maximum failure in Information Density and Semantic Coherence pillars due to the 'Site Maintenance' state. While the site does not use active 'fluff' marketing language, the total absence of promised substance (Signal-Substance gap) triggers high forensic penalties. The score is prevented from reaching 90+ only because there is no active deception or industry cliché match present in the bot-blocking text."*

### ANALYSIS DISCLOSURE & SOURCE ATTRIBUTION

This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website's machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.

Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.

You are encouraged to visit the live site at <https://eylea.us> to view the most current version of its content and see directly what this company is about and what it offers.

Verified Analysis Date: May 30, 2026

**(c) 1EuroSEO Independent Evaluator - Non-Sponsored Result**